News & Events

IHC or IF: Which is Best for My Study?

Immunohistochemistry (IHC) and immunofluorescence (IF) are molecular assays that involve the use of antibodies to detect specific proteins within tissues on microscope slides

Immunohistochemistry for Nonclinical Studies

IHC is a valuable tool that can be used during most phases of drug development. It assists with target validation during early discovery projects and can help determine efficacy and safety during later phases of research and development.

An Overview of IHC Staining Procedures for Formalin-Fixed, Paraffin-Embedded (FFPE) Tissues

Immunohistochemistry (IHC) is a molecular assay that involves the use of antibodies to detect specific proteins within tissues on microscope slides.

4 Benefits of Outsourcing Your IHC Histopathology

As any scientist knows, a lot can go wrong during an experiment. Once you have your final samples and you’re ready for analysis, that’s not the time to be taking any chances.

How to Identify Human Stem Cells in Animal Tissues

Stem cell therapy has advanced significantly over the last decade. In particular, it has shown promising results in regenerating cells in certain tissues of critical importance for life but limited natural ability to regenerate, including the central nervous system and myocardium.

Seven Significant Benefits of Outsourcing Histopathology

Time is of the essence in the realm of contract research organizations, academic institutions, pharma and biotech -- but so are accuracy and affordability.

Frozen vs. Formalin-Fixed Paraffin-Embedded Tissue Sections for IHC

Are you considering the addition of immunohistochemistry (IHC) to your preclinical toxicology study design? IHC integrates molecular pathology and traditional histopathology to allow the visualization of test compounds or cellular targets in situ.

Upcoming Events

SQA

Date: April 6-11
Location: Aurora, CO

ARVO

Date: May 5-9
Location: Seattle, WA
Booth #2212

ASGCT

Date: May 7-11
Location: Baltimore, MD
Booth #1444

Learn more about StageBio’s COVID-19 response